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Objective: To investigate the outcome of patients with early-stage primary fallopian tube carcinomas
(PFTC) and those of patients with equivalent-stage serous epithelial ovarian carcinomas (SEOC).
Materials and methods: A balanced and matched, caseecontrol comparison was conducted in a
university-based tertiary hospital database between 1978 and 2007. All PFTC and SEOC patients were
treated with complete staging surgery followed by multiagent chemotherapy. One SEOC control was
matched for each PFTC patient in a very uniform manner (characteristics and treatment). Disease-free
survival (DFS) and overall survival (OS) were then compared using Kaplan-Meier analysis.
Results: Twenty-six paired patients were analyzed. Patients with PFTC were signiﬁcantly older than the
SEOC patients (58 years vs. 51 years, p ¼ 0.001). In terms of recurrence, PFTC patients frequently had an
extra-abdominal metastasis (3/4, 75%), in contrast to the SEOC patients, who did not (1/5, 20%). The 5-
year DFS rate was similar in both groups (85% vs. 81%, p ¼ 0.05), contributing to a similar OS rate
(89% vs. 85%, p ¼ 0.50). The median DFS and OS of patients with PFTC and SEOC were also similar without
a statistically signiﬁcant difference (125 months vs. 109 months, and 125 months vs. 122 months,
respectively).
Conclusion: Our study demonstrated that the survival outcome of International Federation of Gynecology
and Obstetrics (FIGO) I/II PFTC patients was similar to that of FIGO I/II SEOC patients, and both groups had
a >80% 5-year DFS rate after complete staging surgery, followed by multiagent chemotherapy. This
ﬁnding is worthy of being investigated.
Copyright © 2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
The relative rarity of primary fallopian tube carcinoma (PFTC)
has presented a major challenge to the comprehensive study of the
disease [1,2], and has contributed to uncertainty about the optimal
management [3e5]. The traditional belief is that the survival ratesepartment of Obstetrics and
of Medicine, Taipei Veterans
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bstetrics & Gynecology. Publishedof patients with PFTC are poor, and worse than those of patients
with equivalent stages of serous epithelial ovarian carcinoma
(SEOC) or other early-stage gynecologic malignancies [6]. However,
this conceptmay not really reﬂect the real situation [7]. The reasons
include the following. Among early-stage [International Federation
of Gynecology and Obstetrics (FIGO) Stage I/II] patients, past esti-
mates of outcome may be confounded by the lack of complete
staging surgery, including para-aortic and pelvic lymphadenectomy
in many cases [8], resulting in underestimated FIGO staging. The
National Cancer Institute's Surveillance Epidemiology and End
Results program reported that 47% of patients identiﬁed as having
Stage I/II PFCT had neither a para-aortic nor a pelvic lymph nodeby Elsevier Taiwan LLC. All rights reserved.
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conﬂicted data, which demonstrated better outcomes of early-
stage PFTC than those of SEOC, not only for the 5-year overall
survival (OS; 95% vs. 76%, p¼ 0.02), but also 5-year progression-free
survival rates (79% vs. 65%, p ¼ 0.04) [7]. However, since the ma-
jority of high-grade SEOCs were recently suggested to start in the
fallopian tube [9], we could imagine that the outcomes would be
similar.
Therefore, we conducted this retrospective caseecontrol trial to
prove the above hypothesis.
Materials and methods
Literature review
An extensive literature review up to January 20, 2014 was con-
ducted. We used the following strategies to identify the publica-
tions addressing survival of patients with PFTC and comparison
between PFTC and serous ovarian carcinoma. The term “primary
fallopian tube carcinoma and survival” was used to search PubMed
(http://www.ncbi.nlm.nih.gov/pubmed/?term¼primaryþfallopian
þtubeþcarcinoma%2Cþsurvival) and the term “comparison, pri-
mary fallopian tube carcinoma, serous ovarian carcinoma” in place
of the term “primary fallopian tube carcinoma and survival” (http://
www.ncbi.nlm.nih.gov/pubmed/?term¼comparison%2Cþprimary
þfallopianþtubeþcarcinoma%2Cþserousþovarianþcarcinoma)
was used for relevant articles to identify 344 and 10 published ar-
ticles, respectively. Appropriate references cited by the retrieved
studies were also identiﬁed. Then, the title and subtitle were read
to exclude inappropriate or unrelated articles. Case reports (patient
number < 10) were also excluded. Relevant abstracts were read to
obtain data addressing the 5-year disease-free survival (DFS) rate or
5-year OS rate of early-stage (FIGO I and II) PFTC.Fig. 1. FlowStudy population of the Taipei Veterans General Hospital
The cases (n ¼ 79) reported between 1978 and 2007 [10] were
deﬁned as those of patients identiﬁed as having PFTC per diagnostic
criteria revised by Sedlis [11] including: (1) the main tumor arises
from the endosalpinx; (2) the histological pattern reproduces the
epithelium of tubal mucosa; (3) the transition from benign to
malignant tubal epithelium is demonstrable; and (4) the ovaries or
endometrium are either normal or contain a tumor that is smaller
than the tumor in the tube. Additional inclusion criteria included
only a serous histology (n ¼ 67) and that all patients were treated
with complete staging surgery (cytology, total hysterectomy,
bilateral salpingo-oophorectomy, retroperitoneal lymphadenec-
tomy, omentectomy, appendectomy, and multiple biopsies or ex-
cisions for tumors), followed bymultiagent chemotherapy (n¼ 58).
Because the purpose of this study was focused on early-stage PFTC,
women with advanced-stage PFTC (FIGO III and IV) were excluded.
Fig. 1 shows how we obtained the ﬁnal study population. The
original pathology, including the matched early-stage SEOC, was
reviewed by one author (gynecologic pathologist) and another in-
dependent colleague. After obtaining approval from the Institu-
tional Review Board, the hospital course and clinical follow-up data
were analyzed. All controversial diagnostic cases were excluded
from this study. Because this study was a retrospective chart re-
view, no informed consent was needed. The follow-up period was
calculated from the date of initial surgery to the date of last follow-
up (October 31, 2013) or the time of death. Cross-tabulations,
descriptive statistics and recurrence data were prepared with the
SAS statistical package, version 9.3 (SAS Institute, Cary, NC, USA).
The cut-off value of age and preoperative serum level of carbohy-
drate antigen (CA) 125 was calculated using a receiver operating
characteristic curve. Survival curves were estimated by the Kaplan-
Meier method. Comparisons of all survival curves were done usingchart.
Table 2
Characteristics of the patients.
PFTC SEOC p
Number of patients 26 26
Age (y) 58 ± 9 51 ± 4 0.001
Menopause 20 (77) 13 (50) 0.044
Nulliparity 3 (12) 3 (12) 0.666
FIGO stage >0.99
I 20 (77) 20 (77)
II 6 (23) 6 (23)
Cell grade >0.99
Low-grade 17 (65) 17 (65)
High-grade 9 (35) 9 (35)
Symptoms 0.081
Abdominal pain or fullness 8 (31) 13 (50)
Watery discharge or bleeding 6 (23) 1 (4)
Asymptomatic 12 (46) 12 (46)
Preoperative serum level of CA 125 70 ± 92 33 ± 18 0.052
Comprehensive lymphadenectomy
Number of removed pelvic LN 22 ± 7 21 ± 6 0.530
Number of removed para-aortic LN 4 ± 3 3 ± 2 0.558
Chemotherapy cycles (<6 cycles) 0.139
<6 cycles 6 (23) 11 (42)
6 cycles 20 (77) 15 (58)
Chemotherapy regimen 0.780
Cyclophosphamide-based regimen 11 (42) 12 (46)
Paclitaxel-based regimen 15 (58) 14 (54)
Recurrence 0.500
Yes 4 (15) 5 (19)
No 22 (85) 21 (81)
Recurrence site 0.244
No recurrence 22 (85) 21 (81)
Pelvic and abdominal cavity 1 (4) 4 (15)
Others 3 (12) 1 (4)
5-y DFS rate 22 (85) 23 (89) 0.500
Median DFS mo (range) 125 (16e325) 109 (10e301) 0.886
OS rate 23 (89) 22 (85) 0.500
Median OS mo (range) 125 (34e325) 122 (34e310) 0.841
Data are presented as n (%) or mean ± SD, unless otherwise indicated.
CA 125 ¼ carbohydrate antigen 125; DFS ¼ disease-free survival;
FIGO ¼ International Federation of Gynecology and Obstetrics; LN ¼ lymph node;
OS ¼ overall survival; PFTC ¼ primary fallopian tube carcinoma; SEOC ¼ serous
epithelial ovarian carcinoma.
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USA). This test was also used to select variables to be included in the
log-rank analysis. Signiﬁcance was declared as p < 0.05.
Results
Data of literature review
Finally, data from a total of 11 published articles were obtained,
and a marked variation in the 5-year DFS rate and 5-year OS rate
among these early-stage PFTC patients, ranging from 16% to 95%
(Table 1), was found [1,6,8,12e19]. Only one article showed a direct
head-to-head comparison between PFTC and SEOC [7].
Our experiences
Twenty-six patients with a diagnosis of early-stage (FIGO I and
II) PFTC [20] and who met all inclusion criteria were identiﬁed.
They were matched in a 1:1 fashion with SEOC patients per set
matching and were matched with the inclusion criteria. Matching
criteria included age (±5 years), serous histologic type, complete
staging surgery with equivalent FIGO stages, nulliparity, cell grade,
and adjuvant chemotherapy either paclitaxel-based or
cyclophosphamide-based. The median follow-up was 125 months
(34e325 months) and 122 months (34e310 months) for PFTC and
SEOC patients, respectively.
The mean age of the PFTC and SEOC patients was 58 years and
51 years, respectively. This difference was statistically signiﬁcant
with p ¼ 0.001 (Table 2). PFTC patients had marginally signiﬁcantly
higher serum levels of preoperative CA 125 than the SEOC patients
(70 U/mL vs. 33 U/mL, p ¼ 0.052). There was no statistically sig-
niﬁcant difference in chemotherapy regimen and cycles between
the two groups. Recurrence was documented in 15% of the PFTC
patients and 19% of the SEOC patients. The characteristics of the
patients who had recurrent disease in both groups are shown in
Table 3. The majority of the recurrent PFTC patients had an
extraperitoneal recurrence (3/4, 75%); by contrast, few SEOCTable 1
Five-year disease-free survival (DFS) rates and 5-year overall survival (OS) rates of







FeU 5-year DFS rate or
5-year OS rate (%)
Pectasides (2009) [12] 64/61 29 (45) 40 62
Rosen (1994) [13] 68/60 68 (100) 72 51
Pfeiffer (1989) [14] 52/60 35 (67) 46 64 of Stage I; 40
of Stage II
Rosen (1994) [15] 66/62 36 (55) NA 50
Vaughan (1998) [6] 37/57 27 (73) NA 69 for Stage I, 26
for II
Rosen (1999) [16] 143/63 87 (61) 29 59
Rosen (2000) [17] 63/61 35 (56) NA 59
Klein (2000) [18] 95/NA 95 (100) NA 58 (without CSR) and
83 (with CSR)








127/64 91 (72) NA 62 for Stage I and 16
for Stage II
Current study 26/58 26 (100) 125 85 for Stage I and 100
for Stage II
Age ¼mean or median age in years; CSR ¼ complete surgical resection; early-stage
PFTC ¼ Stage I and II primary fallopian tube carcinoma; FeU ¼ mean or median
follow-up (months); NA ¼ no data available, No. ¼ number of patients.patients did (1/5, 20%), suggesting that the follow-up strategy
should not be limited on intraperitoneal recurrence for PFTC
patients. The original FIGO stage of all recurrent patients in
both groups was FIGO Stage I. Over 75% of patients (n ¼ 7) who
had recurrence were treated with a cyclophosphamide-based
chemotherapy.Table 3
Clinical ﬁndings of patients with early-stage primary fallopian tube serous carci-
noma (PFTC) and serous epithelial ovarian carcinoma (SEOC).
Case Age (y) FIGO
stage
CA 125 PLN PaLN Cycles CT Time Recurrence
site
PFTC 1 72 I 79 14 2 3 CAP 15.6 NO
PFTC 2 74 I 60 34 3 6 CAP 23.2 NO
PFTC 3 64 I 77 13 3 6 PC 30.4 YES
PFTC 4 54 I 45 19 5 6 CAP 39.5 NO
SEOC 1 48 I 11 15 2 6 CAP 94.8 YES
SEOC 2 57 I 23 19 2 3 CAP 21.9 YES
SEOC 3 44 I 17 21 3 6 CAP 9.6 YES
SEOC 4 51 I 22 31 5 3 CAP 88.2 NO
SEOC 5 51 I 33 19 2 3 PC 21.6 YES
CA 125 ¼ carbohydrate antigen 125 (U/mL); CAP ¼ cyclophosphamide, adriamycin
(or epirubicin) and cisplatin; CT¼ chemotherapy regimen was used; Cycles¼ cycles
of chemotherapy administered postoperatively; FIGO ¼ International Federation of
Gynecology and Obstetrics; NO ¼ presence of extraperitoneal recurrence accom-
panied with or without intraperitoneal recurrence; PaLN ¼ number of removed
para-aortic lymph nodes; PC ¼ paclitaxel and carboplatin (cisplatin); PLN ¼ number
of removed pelvic lymph nodes; Time ¼ time to relapse (months); YES ¼ only
intraperitoneal recurrence.
Fig. 3. Overall survival curves of patients with primary fallopian tube carcinoma
(PFTC) compared to matched patients with serous epithelial ovarian carcinoma (SEOC).
These curves are not statistically signiﬁcantly different.
H.-C. Horng et al. / Taiwanese Journal of Obstetrics & Gynecology 53 (2014) 547e551550The 5-year DFS rate was 85% for the PFTC patients and 89% for
the SEOC patients (Fig. 2). The OS rate had a similar absence of
difference, with 89% for the PFTC patients and 85% for the SEOC
patients (Fig. 3). The median of DFS and OS for the PFTC patients
was 125months, respectively, whichwas similar to that of the SEOC
patients (109 months and 122 months, respectively). There was no
statistical difference.
Discussion
The outcome of PFTC has been determined largely from a
retrospective study of cases [3]. Although a comparison study of
PFTC and SEOC is also available in the literature [7], there were
many limitations in the study by Moore et al [7], including: (1) the
majority of early-stage PFTC patients were treated with adjuvant
therapy (91%), but Stage IA SEOC patients from each control were
not treated with adjuvant therapy, which resulted in an imbalance
in the matched Stage IA patients; in addition, more stage IC SEOC
patients were enrolled; and (2) the characteristics of the matched
patients might not be similar; for example, BRCA1/2 mutations
might inﬂuence the chemotherapy response. The present study,
however, is the only matched comparison study of early-stage PFTC
and early-stage SEOC in which the two groups were treated in a
very uniform manner with a comprehensive staging surgery fol-
lowed by multiagent chemotherapy. In addition, BRCA1/2 are
extremely rare in the Taiwanese population [21], and can be
neglected in this study.
Comprehensive staging surgery, especially including careful
para-aortic and pelvic lymphadenectomy, is of greatest importance
in patients with suspected early-stage PFTC. Surgery without
lymphadenectomymay result in underestimating the clinical stage;
i.e., some of the cases identiﬁed as Stage I or II during operation
should actually be classiﬁed as Stage IIIC, since metastases of the
lymph nodes must be expected in as many as 30% of cases intra-
operatively staged as Stage II [22]. In our study, ﬁve patients with
PFTC had pelvic lymph node or para-aortic lymph node metastases
without accompanying gross intraperitoneal carcinomatosis or
massive ascites. If these patients had not received systemic lym-
phadenectomy, they might have been underestimated as early-
stage PFTC. Therefore, the rate of upstaging of apparently earlyFig. 2. Disease-free survival curves for patients with primary fallopian tube carcinoma
(PFTC) compared to matched patients with serous epithelial ovarian carcinoma (SEOC).
These curves are not statistically signiﬁcantly different.stage disease could be estimated as 16% (5/31). This supports data
from a literature review indicating that patients with PFTC have a
higher rate of retroperitoneal and distant metastases than those
with SEOC [3]. PFTC is richly permeated with lymphatic channels
that drain into the para-aortic lymph nodes through infundibulo-
pelvic lymphatics, and are found in 33% of patients in all stages of
disease [23]. There is an almost equal involvement of the para-
aortic and pelvic lymph nodes [24]. Koo et al [25] found that se-
lective pelvic or para-aortic lymphadenectomy could miss lymph
node involvement and lead to an error in staging, suggesting that a
comprehensive retroperitoneal lymphadenectomy, including both
para-aortic and pelvic lymphadenectomy, is an important proce-
dure, particularly since the rates of isolated pelvic and para-aortic
lymphatic metastases were 2.4% and 22.0%, respectively. Klein
et al [22] further found that radical lymphadenectomy increased
median survival to 43months [95% conﬁdence interval (CI) 20e66],
compared to 21 months (95% CI 10e32) without lymphadenec-
tomy, although both did not reach a statistically signiﬁcant differ-
ence (p¼ 0.095). However, Klein and colleagues [22] still suggested
that radical lymphadenectomy in tumors of equal size may mark-
edly prolong survival. The strength of the current study was that all
patients in both groups underwent a uniform but standard
comprehensive surgical staging surgery to obtain the accurate FIGO
stage.
In addition, the proportion of patients receiving a standard
regimen and number of cycles of a paclitaxel/platinum combina-
tion for adjuvant therapy was equivalent, because patients in both
groups were likely to be treated with a cyclophosphamide-based
chemotherapy for ﬁrst-line adjuvant therapy, based on the policy
of the National Health Insurance Bureau (NHIB), Taipei, Taiwan.
These two regimens were tested for therapeutic equivalency and
were found to have signiﬁcant differences in efﬁcacy [26]. In our
study, slightly more patients in both groups were treated with
paclitaxel-based chemotherapy (58% vs. 54%, p ¼ 0.780), without a
statistically signiﬁcant difference.
Our study showed that PFTC patients had a higher serum level of
CA 125 than SEOC patients, but without statistical signiﬁcance. The
possible roles of CA 125 in both PFTC and SEOC patients have been
reported to be an independent prognostic factor for DFS and OS, a
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marker for tumor progression during follow-up [27]. However, the
role of CA 125 in the current study is not clear, because the pre-
operative serum level of CA 125 did not contribute to the DFS and/
or OS.
Considering the strong tendency of PFTC to spread lymphati-
cally, a systematic pelvic and para-aortic lymphadenectomy is
preferred to lymph node sampling [27]. In this study, although the
difference in recurrent sites between the two groups did not reach
statistical signiﬁcance, we still found that PFTC patients frequently
had an extra-abdominal metastasis, in contrast to the SEOC pa-
tients, who often presented with intra-abdominal or pelvic recur-
rence (Tables 1 and 3). This may suggest that PFTC is a generalized
systemic disease, even in its early stage (FIGO I/II). Therefore, we
support the view of Rosen et al [16] and that of our previous study
[4] that patients with FIGO IA PFTC, in particular, should receive
adjuvant treatment.
In conclusion, the standard therapeutic guideline for early-stage
PFTC patients is still uncertain. In addition, of most importance, we
did not compare different treatment modalities for patients with
early-stage PFTC. Therefore, more evidence is needed to decide
whether comprehensive staging surgery followed by chemo-
therapy with a paclitaxel/platinum combination should be per-
formed routinely for those patients with supposed early-stage
PFTC. Furthermore, the number of patients included in this study
was relatively small, because early PFTC is a rare disease. The
ﬁndings in the current study may not be strong enough to conclude
that there was an identical outcome in early-stage SEOC and early-
stage PFTC, based on the limited number of recurrent disease cases
in both groups. In terms of DFS and OS, our current study found that
the outcomes of the two groups were similar if a very similar
uniform treatment, including comprehensive surgical staging sur-
gery followed by multiagent chemotherapy, was used in the man-
agement of these patients who had surgico-pathologically
conﬁrmed early-stage SEOC or PFTC. Therefore, we believe that
adequate staging surgery might provide an accurate stage for pa-
tients with either SEOC or PFTC, since the most important prog-
nostic factor for these patients is the actual disease stage. In the
present study, we also found that 78% of recurrent cases, both early-
stage PFTC and SEOC, were originally treated with a
cyclophosphamide-based chemotherapy as the ﬁrst-line adjuvant
chemotherapy, suggesting that this regimen might not be an
appropriate choice for these patients. By contrast, a paclitaxel-
based chemotherapy might be a better choice. Of course, a larger
sample size or multicenter study would be welcome to conﬁrm the
above observation.
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